Dressing Offers a Highly Effective and Affordable New Option to Help Combat the Escalating MRSA Crisis
PRINCETON, N.J., Feb. 27 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced today that its first BIOGUARD Barrier Dressings have received clearance from the U.S. Food and Drug Administration for marketing and distribution. BIOGUARD will offer surgeons, wound care clinicians, infection control experts and primary care doctors a new weapon against the transmission of such virulent bacteria as Methicillin-resistant Staphylococcus aureus (MRSA). Coming on the heels of Derma Sciences' successful launch of its MEDIHONEY(TM) dressing line in 2008, BIOGUARD is the company's latest new product entrant into the $14 billion global wound care market. Sales of the dressings are expected to commence in June, 2009.
Speaking about the FDA clearance, Derma Sciences' CEO Ed Quilty stated, "This clearance represents a significant milestone for Derma Sciences and provides another large step in implementing our strategic plan. We believe that BIOGUARD, a cost-effective gauze-based dressing that has been shown to kill 99.999% of MRSA, will be a great asset to healthcare providers as they look for more effective and efficient ways to combat the transmission of virulent pathogens throughout their facilities. Surgical site infections are a serious concern, and with changes in reimbursement, prevention has become a major objective for hospitals." Quilty continued, "This gives our sales reps yet another novel wound care product to sell, and will help Derma Sciences reach our goal of profitability in a quicker timeframe. BIOGUARD will open many new doors for us, especially on the gauze side of the business, a large component of the $14 billion global wound care market."
|SOURCE Derma Sciences, Inc.|
Copyright©2009 PR Newswire.
All rights reserved